Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

Paul J. Bröckelmann, Boris Böll, Daniel Molin, Gundolf Schneider, Sirpa Leppä, Julia Meissner, Peter Kamper, Martin Hutchings, Jacob Haaber Christensen, Ulf Schnetzke, Michael Fuchs, Dennis A Eichenauer, Bastian von Tresckow, Helen Kaul, Peter Borchmann, Alexander Fossa

Blood (2024) 144 (Supplement 1): 3054.

https://doi.org/10.1182/blood-2024-202120

Published: 2024

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Blood (2023) 142 (Supplement 1): 4437.

https://doi.org/10.1182/blood-2023-188449

Published: 2023

Journal Articles

Age-Based Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI) in a Real-World Danish Study: Suboptimal Performance in Older Patients

Rasmus Rask Kragh Jørgensen, Sandra Eloranta, Jacob Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Soerensen, Peter Kamper, Andrew M Evens, Matthew J. Maurer, Susan K Parsons, Angie Mae Rodday, Jenica Upshaw, Tarec Christoffer Christoffer El-Galaly, Lasse Hjort Jakobsen

Blood (2023) 142 (Supplement 1): 4455.

https://doi.org/10.1182/blood-2023-178498

Published: 2023

Journal Articles

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - a Nationwide Danish Cohort Study

Sara Rossetti, Sidsel Jacobsen Juul, Frank Eriksson, Peder Emil Warming, Charlotte Glinge, Tarec Christoffer Christoffer El-Galaly, Jacob Haaber Christensen, Peter Kamper, Peter de Nully Brown, Maja Maraldo, Jacob Tfelt-Hansen, Martin Hutchings

Blood (2023) 142 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2023-172989

Published: 2023

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients

Andreas Kiesbye Øvlisen, MD, Lasse H. Jakobsen, PhD, Kristian Hay Kragholm, Martin Hutchings, MD PhD, Henrik Frederiksen, MD PhD Prof, Peter Kamper, Sandra Eloranta, Caroline Weibull, Ingrid Glimelius, MD PhD, Karin Ekstrom Ekstroem Smedby, Marianne Tang Severinsen, MD PhD, Tarec Christoffer C. El-Galaly, MD

Blood (2019) 134 (Supplement_1): 2841.

https://doi.org/10.1182/blood-2019-122642

Published: 2019

Journal Articles

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Boris Boell, MD, Alexander Fosså, MD PhD, Helen Goergen, Peter Kamper, Sirpa Leppa, MD Prof, Daniel Molin, Julia Meissner, MD, Ellen Ritter, MD, Jacob H. Christensen, Martin Hutchings, MD, Michael Fuchs, Andreas Engert, MD, Carsten Kobe, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 926.

https://doi.org/10.1182/blood-2018-99-119363

Published: 2018

Journal Articles

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Michael Roost Clausen, MD, Sirpa Leppa, MD, Peter de Nully Brown, MD, Jette Soenderskov Goerloev, MD, Michael Panny, MD, Wolfgang Willenbacher, MD, Ida Blok Sillesen, MD, Erik Segel, MD, Hans Bentzen, MD, Michael Thorsgaard, MD, Elisa Jacobsen Pulczynski, MD, Peter Kamper, MD, Lars C. Gormsen, MD, Julie Mortensen, MDcal Student, Grethe Lauritzsen, MD, Thomas Relander, MD PhD, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 1782.

https://doi.org/10.1182/blood.V128.22.1782.1782

Published: 2016

Journal Articles

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Francesco d'Amore, Judit Joergensen, Ida Blok Sillesen, Erik Segel, Hans Bentzen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Bjarne Bach Pedersen, Dorte Gillström, Michael Clausen, Peter Kamper, Trine Silkjaer, Lars C. Gormsen, Sirpa Leppä, Helle Toldbod

Blood (2014) 124 (21): 5435.

https://doi.org/10.1182/blood.V124.21.5435.5435

Published: 2014

Journal Articles

Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Lars C. Gormsen, Cecilia Wassberg, Daniel Molin, Peter Kamper, Gunilla Enblad, Francesco d'Amore

Blood (2014) 124 (21): 5360.

https://doi.org/10.1182/blood.V124.21.5360.5360

Published: 2014

Journal Articles

Identification of Novel Germline Variants in Early-Onset Familial Classical Hodgkin Lymphoma with Exome Sequencing

Outi Kilpivaara, PhD, Heikki Ristolainen, Peter Kamper, Minna Taskinen, PhD, Silva Saarinen, MD PhD, Sirpa Leppä, MD PhD, Francesco d'Amore, Aaltonen A. Lauri, Professor

Blood (2014) 124 (21): 4402.

https://doi.org/10.1182/blood.V124.21.4402.4402

Published: 2014

Journal Articles

Epstein-Barr Virus Status Correlates with Composition and Prognostic Impact of the Tumor Microenvironment in Classical Hodgkin Lymphoma

Peter Kamper, Knud Bendix, Stephen Jacques Hamilton-Dutoit, Bent Honore, Francesco d'Amore

Blood (2012) 120 (21): 52.

https://doi.org/10.1182/blood.V120.21.52.52

Published: 2012

Journal Articles

Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.

Tarec Christoffer El-Galaly, Martin Hutchings, Karen Juul Mylam, Peter de Nully Brown, Anne Bukh, Peter Kamper, Hans Erik Johnsen, Francesco d'Amore

Blood (2012) 120 (21): 2637.

https://doi.org/10.1182/blood.V120.21.2637.2637

Published: 2012

Journal Articles

Monocytosis in the Peripheral Blood At First Relapse/Progression Predicts Poorer Overall and Progression-Free Survival After Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma

Marie Toft-Petersen, Peter Kamper, Signe Albertsen, Louise Secher, Erik Kay Segel, Michael Clausen, Francesco d'Amore, MD, DMSci

Blood (2011) 118 (21): 1559.

https://doi.org/10.1182/blood.V118.21.1559.1559

Published: 2011

Journal Articles

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Elisa Jacobsen Pulczynski, Peter Kamper, Unn-Merete Fagerli, Martin Erlanson, Outi Kuittinen, Alexander Fosså, Bjørn Østenstad, Oystein Fluge, Martin Maisenhølder, Hans Hagberg, Mikael Eriksson, Marie Nordstrøm, Sirpa Leppa

Blood (2011) 118 (21): 1602.

https://doi.org/10.1182/blood.V118.21.1602.1602

Published: 2011

Journal Articles

Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma

Peter Kamper, Maja Ludvigsen, Knud Bendix, Stephen Hamilton-Dutoit, Gabriel A. Rabinovich, Michael Boe Møller, Jens R. Nyengaard, Bent Honoré, Francesco d'Amore

Blood (2011) 117 (24): 6638–6649.

https://doi.org/10.1182/blood-2010-12-327346

Published: 2011

Journal Articles

Correlation between Intratumoral Cellular Microenvironment, Clinicopathological Parameters and Prognosis in Hodgkin Lymphoma.

Peter Kamper, MD, Anne-Sofie Hammer, D.V.M, Stephen Hamilton-Dutoit, M.D, Knud Bendix, M.D., Bent Honoré, M.D., Francesco d’Amore, M.D.

Blood (2007) 110 (11): 2273.

https://doi.org/10.1182/blood.V110.11.2273.2273

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Age-Based Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI) in a Real-World Danish Study: Suboptimal Performance in Older Patients

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - a Nationwide Danish Cohort Study

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Identification of Novel Germline Variants in Early-Onset Familial Classical Hodgkin Lymphoma with Exome Sequencing

Epstein-Barr Virus Status Correlates with Composition and Prognostic Impact of the Tumor Microenvironment in Classical Hodgkin Lymphoma

Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.

Monocytosis in the Peripheral Blood At First Relapse/Progression Predicts Poorer Overall and Progression-Free Survival After Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma

Correlation between Intratumoral Cellular Microenvironment, Clinicopathological Parameters and Prognosis in Hodgkin Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only